Geode Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $190M | Buy |
|
|||||
|
2025
Q1 | $242M | Buy |
|
|||||
|
2024
Q4 | $216M | Buy |
|
|||||
|
2024
Q3 | $229M | Buy |
|
|||||
|
2024
Q2 | $263M | Buy |
|
|||||
|
2024
Q1 | $260M | Buy |
|
|||||
|
2023
Q4 | $276M | Buy |
|
|||||
|
2023
Q3 | $244M | Buy |
|
|||||
|
2023
Q2 | $235M | Buy |
|
|||||
|
2023
Q1 | $258M | Buy |
|
|||||
|
2022
Q4 | $267M | Buy |
|
|||||
|
2022
Q3 | $213M | Buy |
|
|||||
|
2022
Q2 | $205M | Buy |
|
|||||
|
2022
Q1 | $189M | Buy |
|
|||||
|
2021
Q4 | $212M | Buy |
|
|||||
|
2021
Q3 | $179M | Buy |
|
|||||
|
2021
Q2 | $192M | Buy |
|
|||||
|
2021
Q1 | $163M | Buy |
|
|||||
|
2020
Q4 | $180M | Buy |
|
|||||
|
2020
Q3 | $151M | Sell |
|
|||||
|
2020
Q2 | $257M | Buy |
|
|||||
|
2020
Q1 | $176M | Buy |
|
|||||
|
2019
Q4 | $164M | Buy |
|
|||||
|
2019
Q3 | $123M | Buy |
|
|||||
|
2019
Q2 | $155M | Buy |
|
|||||
|
2019
Q1 | $156M | Buy |
|
|||||
|
2018
Q4 | $140M | Buy |
|
|||||
|
2018
Q3 | $150M | Buy |
|
|||||
|
2018
Q2 | $144M | Buy |
|
|||||
|
2018
Q1 | $119M | Buy |
|
|||||
|
2017
Q4 | $129M | Buy |
|
|||||
|
2017
Q3 | $133M | Buy |
|
|||||
|
2017
Q2 | $127M | Buy |
|
|||||
|
2017
Q1 | $116M | Buy |
|
|||||
|
2016
Q4 | $103M | Buy |
|
|||||
|
2016
Q3 | $105M | Buy |
|
|||||
|
2016
Q2 | $82.2M | Buy |
|
|||||
|
2016
Q1 | $83.3K | Buy |
|
|||||
|
2015
Q4 | $101M | Buy |
|
|||||
|
2015
Q3 | $99.4M | Buy |
|
|||||
|
2015
Q2 | $127M | Buy |
|
|||||
|
2015
Q1 | $109M | Buy |
|
|||||
|
2014
Q4 | $70.6M | Buy |
|
|||||
|
2014
Q3 | $54.6M | Buy |
|
|||||
|
2014
Q2 | $46.2M | Buy |
|
|||||
|
2014
Q1 | $49.2M | Buy |
|
|||||
|
2013
Q4 | $47.6M | Buy |
|
|||||
|
2013
Q3 | $43.3M | Buy |
|
|||||
|
2013
Q2 | $31.6M | Buy |
|